Image quality and attenuation values of multi detector CT coronary angiography using high iodine-concentration contrast material: A comparison of the use of iopromide 370 and iomeprol 400 by Kim, Eun Young et al.
      Image quality and attenuation values of multidetector CT coronary 
angiography using high iodine-concentration contrast material: 
A comparison of the use of iopromide 370 and iomeprol 400           
    E UN YOUNG      K IM1,2  ,         D AE WOOK      Y EH1  ,         Y EON HYEON      C HOE  1,         W ON JAE      L EE1     &          H YO KEUN      L IM1           
1Department of Radiology and Cardiovascular Imaging Center, Samsung Medical Center, Sungkyunkwan University School 
of Medicine, Seoul, Republic of Korea, 2Department of Radiology, Gachon University Gil Hospital, Incheon, 
Republic  of  Korea                    
  Background:   Effects of high iodine-concentration contrast material on the image quality of 
coronary CT angiography (CCTA) have not been well evaluated.     
  Purpose:   To compare the image quality and attenuation values of CCTA between patients 
administered iopromide 370 and iomeprol 400 with the use of 64-slice multidetector CT.     
  Material and Methods:   Patients were prospectively enrolled and were randomized into 
two groups (group A, 151 patients received iopromide 370, iodine ﬂ  ux       1.48 g I/s; group 
B, 146 patients received iomeprol 400, iodine ﬂ  ux       1.60 g I/s). CT attenuation was mea-
sured in the coronary arteries and great arteries and measurements were standardized based 
on an iodine ﬂ  ux of 1.50 g I/s. The image quality of 15 coronary artery segments was graded 
by two radiologists in consensus with the use of a four-point scale (1       excellent to 4      
poor enhancement). Non-parametric statistical approaches were used to compare the two 
groups.   
  Results:   The median attenuation values in the coronary arteries were 454 HU and 464 HU for 
iopromide 370 and iomeprol 400, respectively, and they did not differ (  P       0.26). When stan-
dardizing for an iodine ﬂ  ux, signiﬁ  cantly higher attenuation values were found for iopromide 
370 (median     460 HU, range     216 – 791 HU) compared with iomeprol 400 (median     435 HU, 
range       195 – 758  HU)  ( P       0.006). The median image quality score of coronary arterial seg-
ments was 1 (range 1  –  2) for both groups (  P       0.84).   
  Conclusion:   The attenuation values in the coronary arteries after injection of the same amount 
of two high iodine-concentration contrast materials at the same ﬂ  ow rate with different iodine 
ﬂ  uxes are similar with no difference in image quality. With standardization for an iodine ﬂ  ux, 
the attenuation is signiﬁ  cantly higher when using iopromide 370.     
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  The recent development of multidetector CT (MDCT) 
has enabled noninvasive imaging of the coronary 
arteries. Because of rapid cardiac motion, high tem-
poral resolution is essential for cardiac CT tech-
niques and spatial resolution should be sufﬁ  cient 
for depiction of the branches of coronary arteries. 
In addition, optimal enhancement is essential for 
the entire diagnostic process and all diagnostic 
images including curved multiplanar reformation 
and volume-rendering images for coronary arteries 
to ensure reliable results during image post-pro-
cessing. Recent studies have described the use of 
contrast material with high iodine content (370 mg 
I/ml or 400 mg I/ml) for coronary CT angiography 
(CCTA) (1  –  4). However, the effects of high iodine-
  concentration contrast material on the vessel vis-
ibility of CCTA using a 64-slice MDCT have not 
been well evaluated. 
  The purpose of this prospective study was to com-
pare the image quality of CCTA using a 64-slice MDCT 
with two contrast agents with high iodine concentra-
tions (iopromide 370 mg I/ml and iomeprol 400 mg 
I/ml). The attenuation obtained in the coronary arteries 
and the great arteries as well as the subjective degree 
of enhancement in the coronary arterial segments were 
evaluated.  
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  Material and Methods   
 Patient  population 
  From August 2007 to December 2008, 337 consecutive 
patients (206 men and 131 women; mean age, 54       10 
years; age range, 22  –  75 years) referred for CCTA for 
suspected coronary artery diseases were enrolled pro-
spectively in the study. Patients who had arrhythmia, 
renal insufﬁ  ciency (a serum creatinine level more than 
1.5 mg/dl), a history of allergic reaction to contrast 
material, previous history of surgery or stenting for 
coronary artery diseases, heart failure, and women who 
were potentially pregnant or nursing were not eligible 
for study participation. Patients who were unable to 
cooperate with breath-holding for at least 10 s or had 
a body weight above 90 kg or below 40 kg were not 
enrolled, to limit the heterogeneity within the patient 
population. The institutional review board approved 
this study and all patients provided written informed 
consent to participate in this study. Images of the study 
were excluded from the analysis in the presence of poor 
image quality caused by a severe motion artifact, exten-
sive calciﬁ  cation or inappropriate scan coverage. 
  Patients were randomly assigned into two groups by 
the use of permuted block randomization (5), which 
differed with regard to the iodine concentration of the 
contrast agent that was administered. Group A patients 
received iopromide 370 (370 mg I/ml, Ultravist 370; 
Bayer Schering Pharma, Berlin, Germany) and group B 
patients received iomeprol 400 (400 mg I/ml, Iomeron 
400; Bracco Imaging, Milan, Italy). For each patient, 
age, sex, height, and body weight were recorded.     
 MDCT 
  Coronary CT angiography was performed on a 64-row 
detector system (Aquilion 64, Toshiba Medical Sys-
tems, Otawara, Japan) in the craniocaudal direction to 
cover from the aortic root to the caudal end of the heart. 
Before an examination, all patients were instructed to 
take a deep breath and to hold their breath. Patients 
with a prescanning heart rate of 65 beats per minute 
or higher were given 100 mg of metoprolol (Seloken; 
AstraZeneca, Zoetermeer, The Netherlands) orally 
1 hour before CT scanning. Just before the injection 
of contrast material, 0.6 mg nitroglycerin was adminis-
tered sublingually for vessel dilation. 
  The contrast agents were prepared at 37  °  C and were 
injected with an 18-guage needle through the right 
antecubital veins by the use of a dual-syringe power 
injector (Stellant-Dual Flow; Medrad, Pittsburgh, Pa., 
USA). Contrast agents were administered at a rate of 
4 ml/s and were followed by a 40 ml saline ﬂ  ush at the 
same rate (6). The resulting contrast material volume 
and injection rate, respectively, were 70 ml and 4 ml/s 
(total injection time, 17.5 s) for all patients. This pro-
cedure reﬂ  ected a clinical routine that resulted in an 
iodine ﬂ  ux (iodine delivery rate, IDR) of 1.48 g I/s for 
iopromide 370 and 1.60 g I/s for iomeprol 400. The 
IDR was calculated as follows: IDR (g I/s)       [iodine 
concentration (mg I/ml)       contrast  ﬂ  ow (ml/s)]/1000 
mg/g (7). In the analysis, attenuation values in the ves-
sels of the two groups were additionally standardized 
on a ﬂ  ux of 1.50 g I/s for the comparison of the attenu-
ation values as described in the statistics section. 
  Synchronization between the passage of contrast 
material and data acquisition was achieved with the 
use of a real-time bolus tracking technique (SureStart; 
Toshiba Medical Systems, Tokyo, Japan) using a region 
of interest (ROI) positioned in the ascending aorta. The 
trigger threshold inside the ROI was set at 200 HU. The 
main scanning parameters were as follows: number of 
detectors, 64; individual detector width, 0.5 mm; gantry 
rotation time, 400 ms; tube voltage, 120 kVp; tube cur-
rent, 400 mA; feed/rotation, 3.2 mm; feed/second, 8.0 mm. 
A phantom of the American Association of Physicists 
in Medicine (AAPM) was used for the calibration of 
the CT scanner to ensure reproducible measurement 
of CT ROI at a 6-month interval. An acceptable limit 
of the attenuation of water was 0       4 HU. For daily 
quality control of CT, air calibration was used.     
  Image data reconstruction 
  Data collection and analysis were performed using pre-
viously reported methodology (2, 8) with some modiﬁ  -
cations. The data set was reconstructed with retrospec-
tive electrocardiography gating with time windows 
of 70%, 75%, and 80% of the R-R interval for one of 
the mid-diastolic phases of cardiac cycles to represent 
motion-free images. For patients with a heart rate of 
more than 70 beats per minute during scanning, addi-
tional reconstruction of images for systolic phases was 
performed. For patients who showed suboptimal image 
quality on predetermined phases due to variable or high 
heart rates, the best phase for image reconstruction was 
selected after a review of multiphase images of one 
slice at the mid-heart level by 10 ms or 1% interval 
throughout the cardiac cycle. 
  With the use of axial data, an experienced radiologist 
reconstructed the three-dimensional volume-rendered 
images and curved multiplanar reformation images of the 
coronary arteries using commercial software (Aquaris 
ver. 3.5.2.1; TeraRecon, San Mateo, Calif., USA).    
  Evaluation of contrast enhancement in the 
coronary arteries 
  Coronary CT angiography was analyzed by consensus 
of two experienced cardiac radiologists who were E.Y. Kim et al.  984
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blinded to contrast material used. Oblique coronal or 
sagittal sections in the dataset were selected to measure 
the attenuation value objectively using an ROI placed 
at the proximal part of the four main coronary arteries 
(right coronary artery, RCA; left main artery, LM; left 
anterior descending artery, LAD; and left circumﬂ  ex 
artery, LCX) (6). The ROIs were drawn as large as 
possible within the vessels with care taken to avoid 
motion artifacts as well as calciﬁ  cation or soft plaques 
(Fig. 1). The overall visualized length without motion 
artifact of each coronary artery depicted on a curved 
planar reformation image was extracted by the use of 
the standard software and compared for both groups. 
  The readers subjectively evaluated the image quality 
based on a 15-segment American Heart Association 
(AHA) model (9). The proximal, middle, and distal seg-
ments of RCA (segments 1, 2, 3), posterior descending 
branch of RCA (segment 4), LM (segment 5), and the 
proximal, middle, and distal segments of the LAD 
(segments 6, 7, 8), the ﬁ  rst and second diagonal vessels 
(segments 9, 10), proximal and distal LCX (segments 
11, 13), obtuse marginal branch (segment 12), and pos-
terolateral and posterior descending branch of LCX 
(segments 14, 15). For each segment, image quality was 
graded with the use of a four-point scale. Scores were 
deﬁ  ned as grade 1 for excellent (strong homogeneous 
enhancement with sharply deﬁ  ned vessel edges), grade 
2 for good (homogeneous enhancement with mildly 
blurred vessel edges), grade 3 for fair (inhomogeneous 
enhancement with moderately blurred vessel edges), 
and grade 4 for poor (inhomogeneous enhancement 
with markedly blurred vessel edges) image quality. 
Grades 1, 2, and 3 were assumed as scores of diag-
nostic image quality. If the segment was not delineated 
by the ﬁ  eld of view for its hypoplasia or aplasia, it was 
counted  as   “ not  applicable ” .   
  Evaluation of contrast enhancement in the 
great arteries 
  The CT attenuation of both groups was measured 
objectively using the ROI technique at the proximal 
ascending aorta, main pulmonary artery, and distal 
descending thoracic aorta at the level of the inferior 
margin of the heart on axial images (Fig. 2). Con-
sistency of contrast enhancement was also assessed 
by calculation of ROI differences as follows: con-
sistency of contrast enhancement       (attenuation of 
proximal ascending aorta   –   attenuation of distal 
thoracic aorta).     
    Fig. 1.         Curved planar reformation images of coronary CT angiography using iomeprol 400 are shown in a 47-year-old male. The attenuation num-
bers using the region of interest technique of the proximal portion of the coronary arteries were higher than 500 HU for the proximal right coronary 
artery (a), the left main coronary artery and the proximal left anterior descending branch (b), the proximal left circumﬂ  ex artery (c). On subjective 
analysis, 13 segments of the coronary arteries were assessed as grade 1 (posterolateral and posterior descending branch of left circumﬂ  ex artery were 
not found).   Contrast material for CT coronary angiography 985
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  Evaluation of streak artifacts in the right atrium 
  Artifacts due to insufﬁ  cient mixing of contrast mate-
rial in the right atrium were assessed using a four-point 
scale. Scores were deﬁ  ned as grade 1 for no streak 
artifact, grade 2 for a mild streak artifact without an 
obscured vessel segment, grade 3 for a moderate streak 
artifact with a mild but acceptable degree of vessel seg-
ment obscuration, and grade 4 for a severe streak arti-
fact with markedly obscured vessel segments.     
  Evaluation of adverse effects due to 
contrast material 
  Vital signs including heart rate were monitored before 
the injection of contrast material and during CCTA. All 
types of adverse effects of contrast agents were also 
recorded and vital signs were closely monitored during 
CT  examinations.   
 Statistical  analysis 
  Sample size was calculated by assuming that the 
grades of image quality in each coronary segment in 
two groups would not be different. If one supposes that 
the proportion of grade 1 would be 90% in each group 
and that difference in proportions of grade 1 in the two 
groups less than 10% would be regarded as no differ-
ence in them, then one needs 220 patients with 80% 
power and 5% type I error. 
  Demographic data such as sex, age, body mass index 
(BMI), height, baseline heart rate, and patients  ’   char-
acteristics were compared using the chi-squared test 
and Wilcoxon two-sample test as appropriate. The 
attenuation values of the coronary arteries and the great 
arteries and the visualized length of each coronary 
artery without motion artifact were averaged for all 
patients in each group and the overall average was 
used to compare the two groups using Wilcoxon rank 
sum tests for single vessel and   t   test on ranks based 
on a mixed linear model to account for the correlation 
of vessels within the same patient (coronary arteries 
only). All tests were based on ranks as deviances from 
normality were expected for the attenuation values. In 
addition, the attenuation values were standardized for 
an iodine ﬂ  ux of 1.50 g I/s by dividing the attenuation 
values by the iodine ﬂ  ux used and by multiplying by 
1.50 (10). These were analyzed in the same way as for 
the raw attenuation values. The results of subjective 
analysis for the image quality of 15 coronary arterial 
segments graded with the use of the four-point scale 
and streak artifacts of the right atrium were assessed by 
the use of a multinomial regression based on general-
ized estimating equations (GEEs) taking into account 
multiple vessels within the same patient. Independence 
was used as working correlation matrix. The number 
of patients who showed adverse reactions to contrast 
agents was assessed using the chi-square test. All 
tests were performed two-sided;   P   values     0.05  were 
regarded as statistically signiﬁ   cant. Data processing 
and analysis were performed with SPSS (version 10.0; 
SPSS, Chicago, IL, USA) and SAS (version 9.2, SAS 
Institute, Cary, NC, USA).       
 Results  
 Demographic  data 
  Among 337 patients initially recruited for this study, 
297 patients (151 patients in group A and 146 patients 
    Fig. 2. Axial images of coronary CT angiography in the same patient as in Fig. 1 are shown. The attenuation numbers of the great arteries were 506 
HU for the ascending aorta (AA), 256 HU for the main pulmonary artery (PA) (a), and 498 HU for the descending aorta (DA) at the level of the 
inferior margin of the heart as determined on axial images (b). The calculated consistency of contrast material was 8 HU.   E.Y. Kim et al.  986
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in group B) were ultimately included in this investigation. 
Forty patients were excluded from the analysis because 
of poor image quality caused by a severe motion arti-
fact (  n       11), extensive calciﬁ  cation (  n       27) or inap-
propriate scan coverage (  n       2). There were 175 men 
and 122 women (age range, 22 – 75 years; median age, 54 
      10 years). Patients  ’   demographics and characteristics 
were not signiﬁ  cantly different between the two groups 
in terms of sex, age, BMI, height, baseline heart rate, use 
of premedication, and symptoms except atypical chest 
pain (Table 1).    
  Evaluation of contrast enhancement in the 
coronary arteries 
  No differences were found between the median attenu-
ation values (454 HU for iopromide 370 and 464 HU 
for iomeprol 400,   P       0.26) in the coronary arteries in 
the two groups without standardization for an iodine 
reﬂ  ux (Table 2). After standardization for an iodine 
ﬂ  ux of 1.5 g I/s, the median attenuation value for iopro-
mide 370 was higher than that for iomeprol 400 (460 
HU and 435 HU, respectively,   P       0.006) (Table 2, 
Fig. 3a). No signiﬁ  cant effect of the location of vessel 
was found on the attenuation values (  P       0.99 and 
  P      0.99 for raw and standardized values, respectively). 
The median visualized length of the RCA, LAD, and 
LCX depicted on curved planar reformation images 
was not signiﬁ  cantly different between the two groups 
(  P       0.05, each) (Table 3, Fig. 3b). A signiﬁ  cant effect 
of the location of vessel was found on the visualized 
lengths of the three coronary arteries in each group 
(  P      0.0001). 
  A total of 3602 segments of 297 patients were evalu-
able for subjective analysis of contrast enhancement, 
excluding 853 segments for their hypoplasia or aplasia. 
In a subjective assessment with the use of a four-point 
scale, each segment of the coronary arteries showed 
excellent or good contrast enhancement. For iopromide 
370, 91.8% (  n        1699) of 1851 coronary segments 
had a score of grade 1 and the remaining 8.2% (  n       
152) had a score of grade 2. For iomeprol 400, 91.6% 
(  n        1604) of 1751 coronary segments had a score of 
grade 1 and the remaining 8.4% (  n        147) had a score of 
grade 2. There was no signiﬁ  cant difference for the image 
quality score of each coronary segment between the two 
groups (  P       0.84).   
  Evaluation of contrast enhancement in the 
great arteries 
 The median attenuation values of the proximal ascending 
aorta, main pulmonary artery, and descending thoracic 
aorta were not different between the two groups (Table 
4). After standardization for an iodine ﬂ  ux of 1.5 g I/s, 
the median attenuation of proximal ascending aorta and 
descending thoracic aorta were signiﬁ  cantly higher for 
iopromide 370 than for iomeprol 400. 
  The consistency of contrast enhancement calculated 
by ROI differences between the proximal ascending 
aorta and distal thoracic aorta was not signiﬁ  cantly 
different between the two groups. The average con-
sistency of contrast enhancement for iopromide 370 
and iomeprol 400 was 49       47 HU and 55       56 HU, 
respectively (  P       0.12).   
    Table 1. Demographics and baseline characteristics.    
Characteristics Iopromide 370 Iomeprol 400
Comparison, 
  P   value
No. of patients 151 146
No. male (%) 87 (58%) 88 (60%) 0.64  † 
Age (years)  *  55       9  (22 – 75) 52       11  (22 – 75) 0.07 ‡ 
Height (cm)  *  164       8  (145 – 188) 166       8  (148 – 184) 0.26 ‡ 
BMI (kg/m  2 ) *  24.6       3.0  (18.4 – 37.0) 24.8       2.7  (15.8 – 32.3) 0.35 ‡ 
Heart rate (beats per minute)  *  70       11  (50 – 106) 71       11  (42 – 102) 0.24 ‡ 
Hypertension 44 (29%) 45 (31%) 0.75
Diabetes 12 (8%) 17 (12%) 0.28
Smoking 25 (17%) 36 (25%) 0.08
Exertional chest pain 22 (15%) 16 (11%) 0.35
Stable chest pain 35 (23%) 36 (25%) 0.77
Atypical chest pain 26 (17%) 13 (9%) 0.03
Hyperlipidemia 22 (15%) 19 (13%) 0.70
Use of metoprolol 87 (58%) 96 (66%) 0.15
Use of nitroglycerin 116 (77%) 104 (71%) 0.27
      *  Data are mean values with standard deviations, and numbers in parentheses are ranges.     
  † Two-group  chi-squared  test  (two-sided).   
    ‡  Two-group Wilcoxon rank sum test (two-sided).     Contrast material for CT coronary angiography 987
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  Evaluation of streak artifacts in right atrium 
  Nine of 151 patients (6%) in group A and 7 of 146 
patients in group B (5%) showed a mild streak artifact. 
No case showed moderate or severe streak artifacts that 
obscured the right coronary artery.     
  Change of heart rate and adverse effects 
with injection of contrast material 
  There was no moderate or severe adverse reaction to 
the intravenous contrast agent, but 13 patients had a 
mild adverse reaction such as nausea (  n       6), dizzi-
ness (  n       3), and urticaria (  n       4). Group A had eight 
cases (5.3%) with mild adverse reactions (three cases 
of nausea, one case of dizziness, four cases of urticaria) 
and group B had ﬁ  ve cases (3.4%) with mild adverse 
reactions (three cases of nausea, two cases of dizziness). 
There was no signiﬁ  cant difference in the frequencies 
of adverse reactions to the contrast agents between the 
two groups (  P       0.43). All of the patients  ’   symptoms 
were resolved soon after conservative treatment. 
  The average change in the heart rate after injection 
of contrast material was 2.9 beats per minute (median, 
2; range, 0  –  20) for group A and 3.2 (median, 3; range, 
0 – 25) for group B, respectively. For group A, 105 patients 
showed a decrease or no change in heart rate after injec-
tion of contrast material, and 41 patients showed increased 
heart rates (mean, 3.1; median, 3; range, 1  –  20 beats per 
minute). For group B, 111 patients showed a decrease or 
no change in heart rates after injection of contrast mate-
rial and 35 patients showed an increased heart rate (mean, 
3.1; median, 2; range, 1  –  10 beats per minute).     
 Discussion 
  An optimal contrast agent application protocol for 
CCTA is critical as the ability to diagnose coronary 
    Fig. 3.         (a) Boxplot of raw and standardized attenuation values for 
enhanced coronary vessels with   P   values for the comparison of groups. 
The raw attenuation values in the coronary arteries showed no signiﬁ  -
cant difference between two groups with the median attenuation value 
of 454 HU (range 213  –  780 HU) for iopromide 370 (group A, Gr.A) and 
that of 464 HU (range, 208  –  809 HU) for iomeprol 400 (group B, Gr.B), 
respectively (  P       0.26). After standardization with an iodine ﬂ  ux of 
1.5 g I/s, the attenuation using iopromide 370 was signiﬁ  cantly higher in 
the coronary arteries (except LAD,   P       0.0539). (b) Boxplot of visual-
ized length of coronary vessels along with   P   values for the comparison 
of groups. The measurements were similar in both groups.   
    Table 2. Attenuation in the proximal segments of the four coronary arteries.   
Vessel Iopromide 370 Iomeprol 400 Comparison,   P   value
RCA (HU)
n  A        151, n  B        146
457  (219 – 780)
 * 463  (222 – 791)
472  (208 – 809)
 * 442  (195 – 758)
0.2533 † 
0.0245 *  † 
LM (HU)
n  A        151, n  B        146
454  (271 – 746)
 * 460  (275 – 756)
455  (241 – 677)
 * 427  (226 – 635)
0.4756 † 
0.0022 *  † 
LAD (HU)
n  A        151, n  B        146
459  (213 – 778)
 * 465  (216 – 789)
472  (236 – 757)
 * 443  (221 – 710)
0.1031 † 
0.0539 *  † 
LCX (HU)
n  A        151, n  B        146
449  (280 – 716)
 * 455  (284 – 726)
457  (252 – 745)
 * 428  (236 – 698)
0.5194 † 
0.0038 *  † 
Average
n  A        604, n  B        584
454  (213 – 780)
 * 460  (216 – 791)
464  (208 – 809)
 * 435  (195 – 758)
0.2644 ‡ 
0.0060 *  ‡ 
    Data are medians and ranges in parentheses. n  A        number of vessels in group A (iopromide 370); n  B        number of vessels in group B 
(iomeprol 400).     
    *  Attenuation in the proximal segments of the four coronary arteries standardized with an iodine delivery rate of 1.5 g I/s.    
    †  Two-group Wilcoxon rank sum test (two-sided).     
  ‡  t   test (two-sided) on ranks based on a linear mixed model.     
artery disease mainly depends on adequate visualization 
of the coronary arteries. Arterial enhancement is gen-
erally determined by the number of iodine molecules E.Y. Kim et al.  988
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administered. The rate of iodine administration can be 
increased either by increasing the injection ﬂ  ow rate or 
by increasing the iodine concentration of the contrast 
agent (11). However, the degree of arterial enhance-
ment following the intravenous injection of the same 
amount and type of contrast material is highly variable 
among individuals for physiological parameters such as 
cardiac output and central blood volume (11). More-
over, according to   CADEMARTIRI   et al. (12), contrast 
bolus geometry may not only depend on contrast den-
sity and ﬂ  ow but also on contrast volume, bolus chaser, 
and heart diseases. In our study, we strictly controlled 
the factors that could inﬂ  uence the contrast geometry, 
such as the total volume and injection rate of the con-
trast material as well as body weight. 
  Several investigators have reported a major impact 
of different iodine ﬂ   uxes on arterial enhancement 
(7, 10, 13, 14). The arterial enhancement is propor-
tional to the iodine ﬂ  ux; the higher iodine ﬂ  ux, the 
higher the arterial enhancement. The iodine ﬂ  ux can 
be increased by increasing the iodine concentration 
or injection rate (10). Slightly higher attenuation values 
found for iomeprol 400 can be attributed to the higher 
iodine delivery rate (1.60 g I/s) as compared with that 
of iopromide 370 (1.48 g I/s). However, the standard-
ized attenuation values for an iodine ﬂ  ux of 1.5 g I/s 
were shown to be signiﬁ  cantly higher for the use of 
iopromide 370 as compared with iomeprol 400 in 
the proximal ascending aorta, thoracic descending 
aorta, and the average value across the great arteries. 
This advantage was also found in the RCA, LM, and 
LCX and the average across the coronary arteries. The 
higher values for the use of iopromide 370 after stan-
dardization of the iodine ﬂ  ux may reﬂ  ect the effects 
of the different viscosities of the two contrast agents 
(12.6 mPas for iomeprol 400 and 9.5 mPas for iopro-
mide 370 at 37  °  C). The higher viscosity of iomeprol 
400 might result in inhomogeneous mixing and there-
fore a non-superior attenuation value, which seemed to 
be compensated by the higher iodine ﬂ  ux. When the 
viscosity of the contrast agent approaches that of blood, 
mixing of the two ﬂ  uids takes place more easily. This is 
of importance in cardiovascular examinations (15). 
  As a limitation of this study, we did not evaluate 
vessels with atherosclerotic disease with extensive cal-
ciﬁ  cation, because these factors may affect the visu-
alization and attenuation of vessels. We administered 
a total amount of 70 ml of contrast material at a ﬂ  ow 
rate of 4 ml/s regardless of the BMI and height of 
patients. However, the BMI did not differ signiﬁ  cantly 
in the two groups; therefore no bias in the comparison 
between the groups was expected. 
 In  conclusion ,   the image quality of CCTA using 
the same amount of iopromide 370 or iomeprol 400 at 
the same injection rate is similarly excellent with dif-
ferent iodine ﬂ  uxes. With standardization for an iodine 
ﬂ  ux, the attenuation is signiﬁ  cantly higher when using 
iopromide  370.   
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    Table 4. Attenuation in the great arteries.   
Vessel Iopromide 370 Iomeprol 400 Comparison,   P   value
Proximal ascending aorta
 n A        151, n  B        146
447  (156 – 656)
 * 453  (158 – 665)
444  (254 – 682)
 * 416  (238 – 639)
0.2341 † 
0.0164 *  † 
Main pulmonary artery
 n A        151, n  B        146
267  (101 – 674)
 * 271  (102 – 683)
270  (110 – 714)
 * 253  (103 – 669)
0.9291 † 
0.1094 *  † 
Distal thoracic aorta
 n A        151, n  B        146
436  (173 – 725
 * 442  (175 – 735)
450  (56 – 776)
 * 422  (53 – 728)
0.7938 † 
0.0177 *  † 
    Data are medians and ranges in parentheses. n  A        number of vessels in group A (iopromide 370); n  B        number of vessels in group B (iomeprol 400).     
    *  Attenuation in the great arteries was standardized with an iodine delivery rate of 1.5 g I/s.     
    †  Two-group Wilcoxon rank sum test (two-sided).     
    Table 3. Visualized length of three coronary arteries.    
Vessel Iopromide 370 Iomeprol 400
Comparison, 
  P   value
RCA (mm)
n  A        151, n  B        146
121  (47 – 173) 123  (42 – 204) 0.8172 * 
LAD (mm)
n  A        151, n  B        146
167  (70 – 271) 172  (77 – 282) 0.1165 * 
LCX (mm)
n  A        151, n  B        146
157  (64 – 209) 152  (72 – 218) 0.4694 * 
Average
n  A        604, n  B        584
147  (47 – 271) 148  (42 – 282) 0.2005 † 
    Data are medians and ranges in parentheses. n  A        number of vessels 
in group A (iopromide 370); n  B        number of vessels in group B 
(iomeprol  400).   
    *  Two-group Wilcoxon rank sum test (two-sided).     
  †  t   test (two-sided) on ranks based on a linear mixed model.     Contrast material for CT coronary angiography 989
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